A prospective observational study about fatigue in patients with unresectable pancreatic cancer who receive nab-paclitaxel plus gemcitabine therapy

Not Applicable

• Conditions: Patients with unresectable pancreatic cancer

• Registration Number: JPRN-UMIN000021758
• Lead Sponsor: Wakayama Medical University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-04-04
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

Not provided

Exclusion Criteria

1)Patients with severe co-morbidity such as heart failure, renal failure, or bowel obstruction. 2)Patients with pregnancy. 3)Patients with active cancer of other organs. 4)Patients with intorerable of oral medications. 5)Patients who is not suitable for undergoing the study safely.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Evaluation of fatigue using FACIT-F (Functional Assessment of Chronic Illness Therapy-Fatigue) score untill eight weeks after stating chemotherapy.

Secondary Outcome Measures

Name	Time	Method
Evaluation of appetite loss using NRS(Numerical Rating Scale), peripheral neuropathy using PNQ(Patient Neurotoxicity Questionnaire), sensitive disorders using NRS, nutritional data, anemia using CTCAE criteria, accomplishment of chemotherapy schedule, usage rate of G-CSF, steroids etc., and overall survival.